Logo image of 88Q.DE

4BASEBIO PLC (88Q.DE) Stock Fundamental Analysis

FRA:88Q - Deutsche Boerse Ag - GB00BMCLYF79 - Common Stock - Currency: EUR

11  0 (0%)

Fundamental Rating

4

88Q gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 73 industry peers in the Biotechnology industry. 88Q scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. 88Q shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year 88Q has reported negative net income.
88Q had a negative operating cash flow in the past year.
In the past 5 years 88Q always reported negative net income.
88Q had a negative operating cash flow in each of the past 5 years.
88Q.DE Yearly Net Income VS EBIT VS OCF VS FCF88Q.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

88Q has a Return On Assets (-27.57%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -46.75%, 88Q is in line with its industry, outperforming 52.05% of the companies in the same industry.
Industry RankSector Rank
ROA -27.57%
ROE -46.75%
ROIC N/A
ROA(3y)-45.31%
ROA(5y)-32.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
88Q.DE Yearly ROA, ROE, ROIC88Q.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

88Q's Gross Margin of 67.52% is fine compared to the rest of the industry. 88Q outperforms 63.01% of its industry peers.
88Q's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for 88Q so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.33%
GM growth 5YN/A
88Q.DE Yearly Profit, Operating, Gross Margins88Q.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

6

2. Health

2.1 Basic Checks

88Q does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 88Q has been increased compared to 1 year ago.
Compared to 5 years ago, 88Q has more shares outstanding
The debt/assets ratio for 88Q has been reduced compared to a year ago.
88Q.DE Yearly Shares Outstanding88Q.DE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M
88Q.DE Yearly Total Debt VS Total Assets88Q.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

88Q has an Altman-Z score of 4.13. This indicates that 88Q is financially healthy and has little risk of bankruptcy at the moment.
88Q's Altman-Z score of 4.13 is amongst the best of the industry. 88Q outperforms 80.82% of its industry peers.
88Q has a Debt/Equity ratio of 0.57. This is a neutral value indicating 88Q is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.57, 88Q is in line with its industry, outperforming 47.95% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.57
Debt/FCF N/A
Altman-Z 4.13
ROIC/WACCN/A
WACC8.56%
88Q.DE Yearly LT Debt VS Equity VS FCF88Q.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

88Q has a Current Ratio of 11.30. This indicates that 88Q is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 11.30, 88Q belongs to the top of the industry, outperforming 94.52% of the companies in the same industry.
88Q has a Quick Ratio of 11.18. This indicates that 88Q is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 11.18, 88Q belongs to the best of the industry, outperforming 94.52% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.3
Quick Ratio 11.18
88Q.DE Yearly Current Assets VS Current Liabilites88Q.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

7

3. Growth

3.1 Past

The earnings per share for 88Q have decreased strongly by -51.13% in the last year.
The Revenue has grown by 84.39% in the past year. This is a very strong growth!
88Q shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 35.80% yearly.
EPS 1Y (TTM)-51.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-46.4%
Revenue 1Y (TTM)84.39%
Revenue growth 3Y40.28%
Revenue growth 5Y35.8%
Sales Q2Q%125.75%

3.2 Future

88Q is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.83% yearly.
88Q is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 95.98% yearly.
EPS Next Y-2.96%
EPS Next 2Y5.21%
EPS Next 3YN/A
EPS Next 5Y14.83%
Revenue Next Year129.21%
Revenue Next 2Y173.86%
Revenue Next 3Y137.13%
Revenue Next 5Y95.98%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
88Q.DE Yearly Revenue VS Estimates88Q.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
88Q.DE Yearly EPS VS Estimates88Q.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2028 2029 -0.2 -0.4 -0.6 -0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 88Q. In the last year negative earnings were reported.
Also next year 88Q is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
88Q.DE Price Earnings VS Forward Price Earnings88Q.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
88Q.DE Per share data88Q.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.21%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for 88Q!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

4BASEBIO PLC

FRA:88Q (8/4/2025, 7:00:00 PM)

11

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-23 2024-09-23
Earnings (Next)N/A N/A
Inst Owners13.58%
Inst Owner ChangeN/A
Ins Owners10.96%
Ins Owner ChangeN/A
Market Cap170.94M
Analysts84.44
Price Target20.24 (84%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.82%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-8.32%
Revenue NY rev (3m)-8.32%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 158.9
P/FCF N/A
P/OCF N/A
P/B 5.62
P/tB 6.47
EV/EBITDA N/A
EPS(TTM)-1.08
EYN/A
EPS(NY)-1.1
Fwd EYN/A
FCF(TTM)-0.91
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0.07
BVpS1.96
TBVpS1.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.57%
ROE -46.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.52%
FCFM N/A
ROA(3y)-45.31%
ROA(5y)-32.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.33%
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.57
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 168.38%
Cap/Sales 168.38%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.3
Quick Ratio 11.18
Altman-Z 4.13
F-Score5
WACC8.56%
ROIC/WACCN/A
Cap/Depr(3y)276.3%
Cap/Depr(5y)321.58%
Cap/Sales(3y)395.7%
Cap/Sales(5y)363.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-51.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-46.4%
EPS Next Y-2.96%
EPS Next 2Y5.21%
EPS Next 3YN/A
EPS Next 5Y14.83%
Revenue 1Y (TTM)84.39%
Revenue growth 3Y40.28%
Revenue growth 5Y35.8%
Sales Q2Q%125.75%
Revenue Next Year129.21%
Revenue Next 2Y173.86%
Revenue Next 3Y137.13%
Revenue Next 5Y95.98%
EBIT growth 1Y-49.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-19.65%
EBIT Next 3Y9.16%
EBIT Next 5Y15.26%
FCF growth 1Y-60.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-73.91%
OCF growth 3YN/A
OCF growth 5YN/A